I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023

I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced that two poster presentations featuring preclinical data on givastomig (also known as TJ-CD4B/ABL111) and TJ-L14B/ABL503, the Company's 4-1BB-targeting bispecific antibody assets, will be reported at the 38th Society for Immunotherapy o

Related Keywords

China ,South Korea ,Xuejun Liu ,Jaeho Jung ,Tyler Ehler ,Bio Kosdaq ,Gigi Feng ,Nasdaq ,Drug Administration ,Twitter ,Linkedin ,Exchange Commission ,Orphan Drug Designation ,Private Securities Litigation Reform Act ,Bispecific Antibody ,Gastric Cancer ,Itc ,Poster Presentations ,Ommercialization ,Development ,I Mab ,